Lung Transplant Unit, Hospital Universitario y Politécnico La Fe, Universität de Valencia, Valencia, Spain.
Curr Opin Organ Transplant. 2022 Jun 1;27(3):184-190. doi: 10.1097/MOT.0000000000000976.
Infections with multiresistant organisms are an emerging problem, cause early mortality post lung transplantation and are sometimes associated with graft dysfunction. Frequently they raise questions about the selection of lung transplant candidates and therapeutic management post lung transplantation. There are no guidelines and management must be individualized. This review summarizes the available therapeutic options in cases of multidrug-resistant (MDR) organisms and outcomes after lung transplant.
Improvements in diagnosis, new and more effective drugs and the experience gained in the management of these infections in lung transplantation, lead to a more optimistic horizon than that found a decade ago.
Update on the management of Burkholderia cepacia complex, Mycobacterium abscessus complex, Aspergillus spp., Scedosporium spp. and Lomentospora prolificans infections. This review clarifies current posttransplant outcomes and adds a little hope in these scenarios.
耐多药病原体感染是一个新出现的问题，可导致肺移植术后早期死亡，并常伴有移植物功能障碍。它们经常引发关于肺移植候选者选择和肺移植后治疗管理的问题。目前尚无相关指南，管理必须个体化。本综述总结了肺移植后耐多药病原体感染的现有治疗选择和结局。
在诊断、新型和更有效的药物方面取得的进展，以及在肺移植中管理这些感染方面的经验积累，使得前景比十年前更为乐观。
对洋葱伯克霍尔德菌复合体、脓肿分枝杆菌复合体、曲霉菌属、枝顶孢属和 prolificans 属感染的治疗进行更新。本综述阐明了目前肺移植后的结局，并为这些情况下带来了一线希望。
